drugset / Trial / NCT00158730

Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

NCT00158730

Phase 3 Completed 800 enrolled Gilead Sciences
RandomizedSingle-groupDouble-blindTreatment

Summary

To evaluate and compare two AmBisome dosing regimens for the initial treatment of invasive aspergillosis and other filamentous fungal infections diagnosed by modified EORTC criteria in immunocompromised patients, as determined by overall response rates at end of course of treatment.

Timeline

Start
2003-04
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown